Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Title

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator–controlled VOYAGE 1 trial

Authors

Keywords

-

Journal

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

Volume 76, Issue 3, Pages 405-417

Publisher

Elsevier BV

Online

2017-01-05

DOI

10.1016/j.jaad.2016.11.041